Skip to content

Ramosetron, low dose midazolam, and their combination for the prevention of postoperative nausea and vomiting in patients undergoing thyroidectomy

In patients undergoing thyroidectomy, which is more effective for the prevention of postoperative nausea and vomiting among ramosetron, low dose midazolam, and their combination?

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12612000757819
Enrollment
69
Registered
2012-07-16
Start date
2012-08-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Postoperative nausea and vomiting (PONV) frequently develops in patients undergoing thyroidectomy, The present study was undertaken to compare the effects of ramosetron, low dose midazolam, and their combination on PONV in patients following total thyroidectomy. Patients were randomly assigned to one of three groups to receive antiemetics as follows: ramosetron 0.3 mg, low dose nidazolam 75microg/kg, or their combination. PONV, postoperative pain intensity, rescue antiemetics requirement, and side effects were assessed at 0, 6, 12, 24h postoperatively.

Interventions

Before induction of anesthesia, ramosetron 0.3 mg combined with low dose midazolam(75 microg/kg) is injected

Sponsors

Astellas pharma korea, INC.
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

patients undergoing thyroidectimy

Exclusion criteria

severe impairment of bowel motility, insulin-dependent diabetes mellitus, pregnancy or breast feeding, administration of antiemetic medication within 24 h before operation, history of cardiovascular or respiratory disease, active alcohol or drug usage, obesity (body mass index > 35 kg/m2), impaired renal and/or hepatic function

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026